In the life sciences industry, a company’s anticorruption policy inevitably governs how employees engage with foreign healthcare professionals (HCPs) – who are considered foreign government officials (FGOs) under most global anticorruption laws. But many companies are finding that a traditional anticorruption policy focused on how not to interact with FGOs can raise more questions than it answers.
This article discusses the benefits of a stand-alone policy on how to engage with foreign HCPs and how its adoption promotes anticorruption compliance within a business and the growth of the life sciences industry.
Click here to read the article on Life Science Leader’s website.
-
Partner